Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects
- Resource Type
- Authors
- Chloé Herledan; Virginie Larbre; Karen Beny; Juliette Périchou; Pierre Sesques; Amandine Baudouin; Gabriel Brisou; Anne Lazareth; Isabelle Carpentier; Gilles Salles; Hervé Ghesquières; Laure Huot; Anne Gaelle Caffin; Lionel Karlin; Catherine Rioufol; Florence Ranchon; Vérane Schwiertz; Nicolas Vantard
- Source
- PLoS ONE, Vol 15, Iss 12, p e0243309 (2020)
PLoS ONE
- Subject
- Male
Cancer Treatment
Myeloma
Pharmacists
Toxicology
Pathology and Laboratory Medicine
Plasma Cell Disorders
Hematologic Cancers and Related Disorders
White Blood Cells
0302 clinical medicine
Animal Cells
Outpatients
Medicine and Health Sciences
Clinical endpoint
Medical Personnel
030212 general & internal medicine
Multiple myeloma
Aged, 80 and over
Multidisciplinary
Hematology
Middle Aged
Professions
Oncology
030220 oncology & carcinogenesis
Medicine
Female
Cellular Types
Multiple Myeloma
Research Article
medicine.medical_specialty
Neutropenia
Patients
Immune Cells
Science
Immunology
Pharmacist
MEDLINE
03 medical and health sciences
Patient Education as Topic
Internal medicine
Intervention (counseling)
medicine
Humans
Immunologic Factors
Myelomas and Lymphoproliferative Diseases
Adverse effect
Aged
Blood Cells
Toxicity
business.industry
Cancers and Neoplasms
Biology and Life Sciences
Cell Biology
medicine.disease
Health Care
Self Care
Clinical trial
Clinical pharmacy
People and Places
Population Groupings
business
Follow-Up Studies
- Language
- ISSN
- 1932-6203
Long-term multiple myeloma therapy by immunomodulatory drugs (IMiDs) raises the question of management of adverse effects. The aim of this study is to assess the impact of an educational session for patients on the acquisition of knowledge to manage hematologic and thromboembolic adverse effects of IMiDs. In this prospective single-center study, patients attended an educational session with a hospital clinical pharmacist and a nurse. The primary endpoint was the patient’s level of knowledge for the management of IMiDs adverse effects, assess with a dedicated questionnaire administered before the session then 1 and 6 months after. Assessment of knowledge was combined with self-assessment of certainty. The secondary endpoints were adherence and IMiD treatment satisfaction. 50 patients were included. Patient knowledge increased at 1 month (p